Form 4: ResMed Director Peter C. Farrell Sells 2,000 Shares Under 10b5-1 Plan
SEC Form 4 Filing
Peter C. Farrell, a director at ResMed Inc., sold 2,000 shares of common stock on October 2, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Peter C. Farrell, Chairman Emeritus and a director at ResMed Inc., sold 2,000 shares of ResMed Common Stock on October 2, 2024.
- The sale was executed at a price of $237.2 per share.
- The transaction was conducted under a Rule 10b5-1 plan adopted on May 28, 2024.
- Following the transaction, Farrell directly owns 85,204 shares of ResMed Common Stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating a routine stock sale by a company director. The use of a 10b5-1 plan suggests the sale was pre-planned and does not necessarily reflect a negative outlook on the company.
Industry Context
Sales by insiders are a common occurrence and are often related to personal financial planning. The use of a 10b5-1 plan allows insiders to sell shares at predetermined times and prices, avoiding accusations of trading on inside information.
Stakeholder Impact
- The sale of shares by a director could be perceived negatively by some shareholders, although the use of a 10b5-1 plan mitigates concerns about insider trading.
Key Dates
| Date | Description |
|---|---|
| May 28, 2024 | Date of adoption of the Rule 10b5-1 plan. |
| October 02, 2024 | Date of the stock sale transaction. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.